Listen on the go
CORRECT!
Next question
touchIMMUNOLOGY touchIMMUNOLOGY
Atopic Dermatitis
Watch Time: 3 mins

Laura Carucci, EAACI 2022: Health Burden of Paediatric Atopic Dermatitis and Impact of Probiotic Treatment

Share this Video
Copy Link
Published Online: Jul 22nd 2022

Paediatric atopic dermatitis is a common chronic skin condition in children that results in dry, itchy skin. It was a pleasure to talk with Dr. Laura Carucci (University of Naples Federico II. Naples, Italy) to discuss the health burden of paediatric atopic dermatitis, the unmet needs in treatment and the potential of probiotic treatment.

The abstract ‘The efficacy of the Probiotic L.rhamnosus GG in Pediatric Atopic Dermatitis: results from the ProPAD study.‘ was presented at EAACI 2022, 1-3 July, 2022.

Questions

  1. Could you give us an overview of the health burden of paediatric atopic dermatitis and how it impacts the daily life of patients? (0:16)
  2. What are the unmet needs in the treatment of paediatric atopic dermatitis? (0:56)  
  3. What was known about the impact of probiotics in atopic dermatitis and what questions were unanswered? (1:34)

Disclosures: Laura Carucci has nothing to disclose in relation to this video interview.

Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.

Filmed in coverage of the EAACI Hybrid Congress 2022.

Related Videos In Atopic Dermatitis
Atopic Dermatitis, Dermatological Conditions
Developed by Touch
Amy Paller, Dermatology Meeting News 2023: The efficacy of dupilumab in children with atopic dermatitis
Watch Time: 9 mins

Dupilumab is a monoclonal antibody approved for use in patients with atopic dermatitis that is not well controlled with topical treatments, or who are unable to use topical treatments. It was a pleasure to talk with Prof Amy Paller (Northwestern University Feinberg School of Medicine; Lurie Children’s Hospital of Chicago, Chicago, IL, USA) about the […]

Atopic Dermatitis, Dermatological Conditions
Developed by Touch
Amy Paller, Dermatology Meeting News 2023: Current treatment paradigm for atopic dermatitis in children
Watch Time: 2 mins

Atopic dermatitis is a chronic skin disorder causing inflammation, redness and irritation of the skin, and usually begins in childhood. touchIMMUNOLOGY caught up with Prof Amy Paller (Northwestern University Feinberg School of Medicine; Lurie Children’s Hospital of Chicago, Chicago, IL, USA), to discuss the current treatment paradigm for atopic dermatitis in children, and factors that […]

Atopic Dermatitis, Dermatological Conditions
Developed by Touch
Melinda Gooderham, Dermatology Meeting News 2023: Abrocitinib efficacy in atopic dermatitis by baseline disease severity – findings from an interim analysis of JADE EXTEND
Watch Time: 3 mins

JADE-EXTEND (NCT03422822) is a phase 3 long-term extension study investigating the efficacy and safety of abrocitinib in atopic dermatitis. In this touchIMMUNOLOGY interview, we caught up with Dr. Melinda Gooderham (SKiN Centre for Dermatology, Ontario, Canada) around her interim analysis of JADE-EXTEND, looking at efficacy by baseline disease severity. The abstract ‘Influence of Baseline Disease […]

Trending In Atopic Dermatitis:

Amy Paller, Dermatology Meeting News 2023: The efficacy of dupilumab in children with atopic dermatitis
Atopic Dermatitis, Dermatological Conditions
    • Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72